Gene info: ID 2898

Gene: GRIK2

GENE ID: 2898

Description: glutamate ionotropic receptor kainate type subunit 2

Gene type: protein-coding

Location: 6q16.3

dbXrefs: Ensembl:ENSG00000164418 MIM:138244 Vega:OTTHUMG00000016328 UniprotKB:Q13002

RefSeq: NG_009224.2

Retrived from: PubMed|SNP Mapped

SNPs: 1 ANCO-SNPs

Phenotype: ND

# Publications: 2

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 1.823e-1 (AD) 2.732e-1 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs6570989	chr6:101509537 (GRCh38.p7)	G>A	nicotine dependence	SNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
SCN2A	0.931
C2CD5	0.928
GPRASP1	0.927
LRRC7	0.924
GPHN	0.921
PAK3	0.919
UNC80	0.918
GRIA1	0.918
ST8SIA3	0.916
ADD2	0.915

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
CNN2	-0.504
WDR38	-0.499
SYDE1	-0.488
RHOD	-0.487
CCDC102A	-0.486
EVC2	-0.484
RAB13	-0.483
HEY2	-0.481
CSAG1	-0.472
ROM1	-0.468

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00142	Glutamic Acid	Small Molecule	56-86-0	Approved\|Nutraceutical	Target
DB00237	Butabarbital	Small Molecule	125-40-6	Approved\|Illicit	Target
DB00241	Butalbital	Small Molecule	77-26-9	Approved\|Illicit	Target
DB00306	Talbutal	Small Molecule	115-44-6	Approved\|Illicit	Target
DB00312	Pentobarbital	Small Molecule	76-74-4	Approved\|Investigational	Target
DB00418	Secobarbital	Small Molecule	76-73-3	Approved	Target
DB00463	Metharbital	Small Molecule	50-11-3	Withdrawn	Target
DB00599	Thiopental	Small Molecule	76-75-5	Approved	Target
DB00794	Primidone	Small Molecule	125-33-7	Approved	Target
DB00849	Methylphenobarbital	Small Molecule	115-38-8	Approved	Target
DB01174	Phenobarbital	Small Molecule	50-06-6	Approved\|Investigational	Target
DB01351	Amobarbital	Small Molecule	57-43-2	Approved\|Illicit	Target
DB01352	Aprobarbital	Small Molecule	77-02-1	Approved\|Illicit	Target
DB01353	Butethal	Small Molecule	77-28-1	Approved\|Illicit	Target
DB01354	Heptabarbital	Small Molecule	509-86-4	Approved	Target
DB01355	Hexobarbital	Small Molecule	56-29-1	Approved	Target
DB01483	Barbital	Small Molecule	57-44-3	Illicit	Target
DB01496	Barbituric acid derivative	Small Molecule		Experimental\|Illicit	Target
DB02852	Domoic Acid	Small Molecule	14277-97-5	Experimental	Target
DB02999	Quisqualate	Small Molecule		Experimental	Target
DB03425	2s,4r-4-Methylglutamate	Small Molecule		Experimental	Target

ID	Drug Name	Action	PubMed
C084273	5-nitro-6,7,8,9-tetrahydrobenzo(G)indole-2,3-dione-3-oxime	"5-nitro-6,7,8,9-tetrahydrobenzo(G)indole-2,3-dione-3-oxime binds to and results in decreased activity of GRIK2 protein"	19596362
D000082	Acetaminophen	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIK2 mRNA	25607892
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of GRIK2 gene	27153756
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of GRIK2 mRNA	16483693
D000726	Androgen Antagonists	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIK2 mRNA	25607892
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of GRIK2 mRNA	24449571
D001565	Benzoates	Benzoates analog binds to and results in decreased activity of GRIK2 protein	14667236
D004958	Estradiol	Estradiol affects the expression of GRIK2 mRNA	22574217
D004958	Estradiol	[Estradiol co-treated with Progesterone] results in decreased expression of GRIK2 mRNA	22154832
D004958	Estradiol	Estradiol results in decreased expression of GRIK2 mRNA	22154832
D004958	Estradiol	[bisphenol A co-treated with Estradiol] results in increased expression of GRIK2 mRNA	26496021
C006780	bisphenol A	bisphenol A results in decreased expression of GRIK2 mRNA	27685785
C006780	bisphenol A	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIK2 mRNA	25607892
C006780	bisphenol A	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK2 mRNA	25607892
C006780	bisphenol A	[bisphenol A co-treated with Estradiol] results in increased expression of GRIK2 mRNA	26496021
C006780	bisphenol A	bisphenol A results in decreased expression of GRIK2 mRNA	25181051
C038091	butylparaben	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIK2 mRNA	25607892
C038091	butylparaben	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK2 mRNA	25607892
C018475	butyraldehyde	butyraldehyde results in decreased expression of GRIK2 mRNA	26079696
C055494	caffeic acid phenethyl ester	[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of GRIK2 mRNA	20360939
D002220	Carbamazepine	Carbamazepine results in decreased expression of GRIK2 mRNA	19596362
D002220	Carbamazepine	Carbamazepine results in decreased expression of GRIK2 protein	19596362
D000068579	Celecoxib	[Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK2 mRNA	21589914
D004390	Chlorpyrifos	Chlorpyrifos results in decreased expression of GRIK2 mRNA	18668222\|1944049
D015283	Citalopram	GRIK2 polymorphism affects the susceptibility to Citalopram	19295509
D003024	Clozapine	Clozapine results in increased expression of GRIK2 mRNA	18923069
D003042	Cocaine	Cocaine affects the expression of GRIK2 protein	15140200
D003907	Dexamethasone	Dexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of GRIK2 mRNA]	27941970
D003976	Diazinon	Diazinon affects the expression of GRIK2 mRNA	19440498
D003993	Dibutyl Phthalate	[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIK2 mRNA	25607892
D003633	Dichlorodiphenyl Dichloroethylene	[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIK2 mRNA	25607892
D004051	Diethylhexyl Phthalate	[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIK2 mRNA	25607892
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of GRIK2 mRNA	20360939
C038939	enzacamene	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIK2 mRNA	25607892
C038939	enzacamene	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK2 mRNA	25607892
C109476	epoxiconazole	[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIK2 mRNA	25607892
D000431	Ethanol	Ethanol results in increased expression of GRIK2 protein	12045474
D005473	Fluoxetine	ADARB1 protein promotes the reaction [Fluoxetine results in increased expression of GRIK2 mRNA]	21320410
D005473	Fluoxetine	ADARB1 protein promotes the reaction [Fluoxetine results in increased expression of GRIK2 protein]	21320410
D005473	Fluoxetine	Fluoxetine results in increased expression of GRIK2 mRNA	21320410
D005473	Fluoxetine	Fluoxetine results in increased expression of GRIK2 protein	21320410
D005473	Fluoxetine	HTR2B protein promotes the reaction [Fluoxetine results in increased expression of GRIK2 mRNA]	21320410
D005473	Fluoxetine	HTR2B protein promotes the reaction [Fluoxetine results in increased expression of GRIK2 protein]	21320410
D006220	Haloperidol	Haloperidol results in increased expression of GRIK2 mRNA	18923069
D007608	Kainic Acid	[Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK2 mRNA	21589914
D007608	Kainic Acid	Kainic Acid results in increased expression of GRIK2 mRNA	17997037
C008261	lead acetate	lead acetate results in increased expression of GRIK2 mRNA	24260418
D008044	Linuron	[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIK2 mRNA	25607892
D008094	Lithium	Lithium results in decreased expression of GRIK2 mRNA	19596362
D008094	Lithium	Lithium results in decreased expression of GRIK2 protein	19596362
D008094	Lithium	[Lithium co-treated with Pilocarpine] results in increased expression of GRIK2 mRNA	16819974
D008767	Methylmercury Compounds	Methylmercury Compounds results in increased expression of GRIK2 mRNA	16966085
D009532	Nickel	Nickel results in decreased expression of GRIK2 mRNA	24768652\|2558310
D009538	Nicotine	Nicotine results in increased expression of GRIK2 mRNA	17997037
C118580	octylmethoxycinnamate	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIK2 mRNA	25607892
C118580	octylmethoxycinnamate	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK2 mRNA	25607892
C476610	oxcarbamazepine	oxcarbamazepine results in decreased expression of GRIK2 mRNA	19596362
C476610	oxcarbamazepine	oxcarbamazepine results in decreased expression of GRIK2 protein	19596362
C046012	pentanal	pentanal results in decreased expression of GRIK2 mRNA	26079696
D010862	Pilocarpine	[Lithium co-treated with Pilocarpine] results in increased expression of GRIK2 mRNA	16819974
D028321	Plant Preparations	Plant Preparations results in decreased expression of GRIK2 mRNA	26945725
C045362	prochloraz	[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIK2 mRNA	25607892
C035988	procymidone	[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIK2 mRNA	25607892
D011374	Progesterone	[Estradiol co-treated with Progesterone] results in decreased expression of GRIK2 mRNA	22154832
D011374	Progesterone	Progesterone results in decreased expression of GRIK2 mRNA	19690047
D011441	Propylthiouracil	Propylthiouracil results in increased expression of GRIK2 mRNA	24780913
D012822	Silicon Dioxide	Silicon Dioxide analog results in decreased expression of GRIK2 mRNA	25895662
C020806	tetrabromobisphenol A	tetrabromobisphenol A results in decreased expression of GRIK2 mRNA	25172293
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of GRIK2 mRNA	11752688\|2387185
D013849	Thimerosal	Thimerosal results in increased expression of GRIK2 mRNA	27188386
D014212	Tretinoin	Tretinoin results in increased expression of GRIK2 mRNA	21934132
C012589	trichostatin A	trichostatin A results in increased expression of GRIK2 mRNA	24935251
D014635	Valproic Acid	Valproic Acid results in increased expression of GRIK2 mRNA	23179753\|2519280
D014635	Valproic Acid	Valproic Acid results in decreased expression of GRIK2 mRNA	19596362
D014635	Valproic Acid	Valproic Acid results in decreased expression of GRIK2 protein	19596362
C025643	vinclozolin	[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIK2 mRNA	25607892
C025643	vinclozolin	vinclozolin affects the expression of GRIK2 mRNA	19015723
D015032	Zinc	Zinc results in increased expression of GRIK2 mRNA	16870260
C016837	zinc chloride	zinc chloride results in increased expression of GRIK2 mRNA	16870260

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005234	extracellularly glutamate-gated ion channel activity	-	IMP	28180184
GO:0008066	glutamate receptor activity	-	IBA	21873635
GO:0015276	ligand-gated ion channel activity	-	TAS	-
GO:0015277	kainate selective glutamate receptor activity	-	IBA	21873635
GO:0015277	kainate selective glutamate receptor activity	-	IDA	15537878
GO:0030165	PDZ domain binding	-	IEA	-
GO:0031624	ubiquitin conjugating enzyme binding	-	IEA	-
GO:0031625	ubiquitin protein ligase binding	-	IEA	-
GO:0042803	protein homodimerization activity	-	IEA	-
GO:1904315	transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001662	behavioral fear response	-	IEA	-
GO:0006874	cellular calcium ion homeostasis	-	IEA	-
GO:0006886	intracellular protein transport	-	IEA	-
GO:0007215	glutamate receptor signaling pathway	-	TAS	7536611
GO:0007268	chemical synaptic transmission	-	TAS	7536611
GO:0019228	neuronal action potential	-	IEA	-
GO:0034220	ion transmembrane transport	-	IEA	-
GO:0035235	ionotropic glutamate receptor signaling pathway	-	IEA	-
GO:0035249	synaptic transmission, glutamatergic	-	IBA	21873635
GO:0035249	synaptic transmission, glutamatergic	-	IEA	-
GO:0043113	receptor clustering	-	IEA	-
GO:0043524	negative regulation of neuron apoptotic process	-	IEA	-
GO:0043525	positive regulation of neuron apoptotic process	-	IEA	-
GO:0046328	regulation of JNK cascade	-	IEA	-
GO:0048169	regulation of long-term neuronal synaptic plasticity	-	IEA	-
GO:0048172	regulation of short-term neuronal synaptic plasticity	-	IMP	15537878
GO:0050804	modulation of chemical synaptic transmission	-	IBA	21873635
GO:0050804	modulation of chemical synaptic transmission	-	IDA	15537878
GO:0050806	positive regulation of synaptic transmission	-	IMP	15537878
GO:0051402	neuron apoptotic process	-	IEA	-
GO:0051967	negative regulation of synaptic transmission, glutamatergic	-	IEA	-
GO:0060079	excitatory postsynaptic potential	-	IEA	-
GO:0060080	inhibitory postsynaptic potential	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005886	plasma membrane	-	IBA	21873635
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	TAS	7536611
GO:0014069	postsynaptic density	-	IEA	-
GO:0030054	cell junction	-	IEA	-
GO:0032839	dendrite cytoplasm	-	IEA	-
GO:0032983	kainate selective glutamate receptor complex	-	IBA	21873635
GO:0032983	kainate selective glutamate receptor complex	-	IEA	-
GO:0042734	presynaptic membrane	-	IBA	21873635
GO:0042734	presynaptic membrane	-	IEA	-
GO:0043195	terminal bouton	-	IEA	-
GO:0043204	perikaryon	-	IEA	-
GO:0045211	postsynaptic membrane	-	IBA	21873635
GO:0045211	postsynaptic membrane	-	IEA	-
GO:0098839	postsynaptic density membrane	-	IBA	21873635

KEGG ID	KEGG Term
hsa04080	Neuroactive ligand-receptor interaction

Reactome ID	Reactome Term	Evidence
R-HSA-112314	Neurotransmitter receptors and postsynaptic signal transmission	TAS
R-HSA-112315	Transmission across Chemical Synapses	TAS
R-HSA-112316	Neuronal System	TAS
R-HSA-451306	Ionotropic activity of kainate receptors	TAS
R-HSA-451307	Activation of Na-permeable kainate receptors	TAS
R-HSA-451308	Activation of Ca-permeable Kainate Receptor	TAS
R-HSA-451326	Activation of kainate receptors upon glutamate binding	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
19268276	Genome-wide association study of smoking initiation and current smoking. (2009 Mar)	Vink JM	Am J Hum Genet
24986733	A non-parametric approach for detecting gene-gene interactions associated with age-at-onset outcomes. (2014 Jul 1)	Li M	BMC Genet